论文部分内容阅读
目的:探讨莫沙比利与瑞巴派特联合治疗慢性萎缩性胃炎的临床效果。方法:选取2014年3月-2015年4月本院收治慢性萎缩性胃炎病例患者90例,随机分为对照组与观察组,各45例,对照组单纯采用莫沙比利进行治疗,观察组患者采用莫沙比利与瑞巴派特联合治疗,观察两组患者的临床治疗效果,幽门螺杆菌根除情况以及不良反应发生情况。结果:治疗后,观察组患者在治疗总有效率,幽门螺杆菌根除率以及不良反应发生率等方面均显著优于对照组(P<0.05)。结论:莫沙比利联合瑞巴派特在慢性萎缩性胃炎临床治疗中效果显著,能够有效降低幽门螺杆菌感染率,减少未知疾病复发的风险,且不良反应极低。
Objective: To investigate the clinical effect of mosapride and rebamipide in the treatment of chronic atrophic gastritis. Methods: From March 2014 to April 2015, 90 patients with chronic atrophic gastritis in our hospital were selected and randomly divided into control group and observation group, 45 cases in each group. The control group was treated with mosapride alone, and the observation group The patients were treated with mosapride and rebamipide, and the clinical efficacy, eradication of Helicobacter pylori and the incidence of adverse reactions were observed in both groups. Results: After treatment, the observation group was significantly better than the control group in terms of total effective rate, Helicobacter pylori eradication rate and the incidence of adverse reactions (P <0.05). Conclusion: Mosapride combined with rebamipide is effective in the treatment of chronic atrophic gastritis. It can effectively reduce the infection rate of Helicobacter pylori, reduce the risk of recurrence of unknown diseases, and has very low adverse reactions.